Increase of CD4+TNFα+IL-2-T cells in cerebrospinal fluid of multiple sclerosis patients

Multiple Sclerosis

Volumn 15, Issue 1, 2009, Pages 120-123

  Shi, N ^a   Kawano, Y ^a   Matsuoka, T ^a   Mei, F J ^a   Ishizu, T ^a   Ohyagi, Y ^a   Kira, J ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Cerebrospinal fluid; Flow cytometry; IL 2; Multiple sclerosis; TNF

Indexed keywords

INTERLEUKIN 2; IONOMYCIN; PHORBOL MYRISTATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; RELAPSE; REMISSION;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CEREBROSPINAL FLUID; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149099562     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508096871     Document Type: Article

References (10)

1. Drulovi J Mostarcia-Stojkovi M Levi Z Stojsavljevi N Pravica V Mesaros S. Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci 1997;147: 145-150.
2. Vladi A Horvat G Vukadin S Suci Z Simaga S. Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 2002; 21: 86-89.
3. Ozenci V Kouwenhoven M Huang YM Kivisäkk P Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis facor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000; 120: 147-153.
4. Laurence A Tato CM Davidson TS. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26: 371-381.
5. Poser CM Brinar VV. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg 2001; 103: 1-11.
6. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
7. Kira J Kanai T Nishimura Y. Western versus Asian types of multiple sclerosis: Immunogenetically and clinically distinct disorders. Ann Neurol 1996; 40: 569-574.
8. Selmaj K Raine CS Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991; 30: 694-700.
9. Liu J Marino MW Wong G. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998; 4: 78-83.
10. van Oosten BW Barkhof F Truyen L. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.